Bengaluru, 18th August 2025 : The unaudited financial statements for the Q1FY26 results have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 86 countries across the globe.
Key Consolidated Financial Highlights:
Particulars | Q1 FY26 | Q1 FY25 |
Revenues (in Rs Cr) | 145.07 | 160.63 |
EBITDA (in Rs Cr) | 51.7 | 62.54 |
EBITDA Margin | 35.6% | 38.9% |
PAT (in RsCr) | 34.79 | 44.64 |
PAT Margin | 24.0% | 27.8% |
Quarterly EPS (in Rs) | 4.3 | 5.5 |
Key Highlights for Q1 FY26:
In Q1 FY26, Supriya Lifescience Ltd. witnessed a 9.7% year-over-year decline in Revenue to Rs 145.07 crore compared to Rs 160.63 crore in Q1 FY25.
EBITDA for Q1 FY26 stood at Rs. 51.70 crore, with an EBITDA margin of 35.6%, as against Rs 62.54 crore in Q1 FY25 with a margin of 38.9%.
The Profit After Tax (PAT) for Q1 FY26 was Rs 34.79 crore, compared to RS 44.64 crore in Q1 FY25.
The PAT Margin stood at 24.0% in Q1 FY26 versus 27.8% in Q1 FY25.
Anaesthetic segment led the revenue in Q1, contributing 53% to the revenue vs 45% in Q1 FY25.
European markets now contribute 41% of our business revenue in Q1 FY26, up from 34% in Q1 FY25.
Capacity Utilisation has recovered from 70% in FY25 to 76% in FY26. In order to support the future growth of various business segments, the company has acquired three separate land parcels near different plants.
Mr. Satish Wagh, Chairman and Managing Director, Supriya Lifescience Ltd, commenting on the results, said, “Our Q1 results reflect a temporary impact from the delay in the production facility campaign due to essential repair and maintenance at our Lote facility. These upgrades were critical to improving the efficiency of our older blocks and enabling full utilisation of Module E for upcoming product launches. Despite the revenue dip, EBITDA margins remained strong at 36%, backed by improved backwards integration and increased contribution from regulated markets. With the Ambernath site progressing towards commercial production in Q4, a strong pipeline of 3–4 product launches in FY26, and healthy demand across key therapeutic areas, we expect the second half to recover the delays from H1. We remain on track to deliver ~20% growth and reach Rs 1,000 crore revenue by FY27.”
ADVERTISEMENT
